Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Sell
25
MREO Quote, Financials, Valuation and Earnings
Last price:
$2.30
Seasonality move
:
71.44%
Day range:
$2.28 - $2.48
52-week range:
$2.22 - $5.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.00x
Volume:
868.1K
Avg. volume:
1.4M
1-year change:
-30.3%
Market cap:
$365.7M
Revenue:
$10M
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$6.4M | -$0.02 | -100% | -71.08% | $7.52 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$9.8M | -$0.13 | 24.19% | -8.33% | $1.77 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $64.50 |
|
VRNA
Verona Pharma PLC
|
$68.5M | -$0.02 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$2.30 | $7.52 | $365.7M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.21 | $1.77 | $53M | -- | $0.00 | 0% | 0.29x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.23 | $17.97 | $822.4K | -- | $0.00 | 0% | 1.11x |
|
NCNA
NuCana PLC
|
$1.28 | $64.50 | $7.8M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$62.70 | $81.00 | $5.3B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.564 | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 2.439 | 36.44% | 2.60x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.756 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | 0.645 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | -0.759 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$14.7M | -- | -- | -- | -$9.4M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Mereo BioPharma Group PLC vs. Competitors
-
Which has Higher Returns MREO or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -2303.38%. Mereo BioPharma Group PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.05 -- ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About MREO or ADAP?
Mereo BioPharma Group PLC has a consensus price target of $7.52, signalling upside risk potential of 226.8%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.77 which suggests that it could grow by 758.62%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 ADAPAdaptimmune Therapeutics PLC2 2 0 -
Is MREO or ADAP More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.520, suggesting its more volatile than the S&P 500 by 152.023%.
-
Which is a Better Dividend Stock MREO or ADAP?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or ADAP?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Mereo BioPharma Group PLC's net income of -$7M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 0.29x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$7M ADAPAdaptimmune Therapeutics PLC0.29x -- $3.2M -$74.2M
-
Which has Higher Returns MREO or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.05 -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About MREO or BDRX?
Mereo BioPharma Group PLC has a consensus price target of $7.52, signalling upside risk potential of 226.8%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1370.86%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is MREO or BDRX More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.
-
Which is a Better Dividend Stock MREO or BDRX?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BDRX?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$7M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 1.11x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$7M BDRXBiodexa Pharmaceuticals PLC1.11x -- -- --
-
Which has Higher Returns MREO or NCNA?
NuCana PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.05 -- NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About MREO or NCNA?
Mereo BioPharma Group PLC has a consensus price target of $7.52, signalling upside risk potential of 226.8%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 4939.06%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 NCNANuCana PLC1 1 0 -
Is MREO or NCNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.789%.
-
Which is a Better Dividend Stock MREO or NCNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or NCNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$7M is lower than NuCana PLC's net income of -$836.1K. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$7M NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns MREO or VRNA?
Verona Pharma PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -92.29%. Mereo BioPharma Group PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.05 -- VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About MREO or VRNA?
Mereo BioPharma Group PLC has a consensus price target of $7.52, signalling upside risk potential of 226.8%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 29.19%. Given that Mereo BioPharma Group PLC has higher upside potential than Verona Pharma PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 VRNAVerona Pharma PLC5 0 0 -
Is MREO or VRNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.
-
Which is a Better Dividend Stock MREO or VRNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or VRNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Mereo BioPharma Group PLC's net income of -$7M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$7M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
